4.3 Article

The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey

Journal

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
Volume 32, Issue 8, Pages 1062-1066

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MEG.0000000000001729

Keywords

biologics; Crohn's disease; immunoprophylaxis; postoperative recurrence; prevention

Funding

  1. AbbVie
  2. Pfizer
  3. Takeda
  4. Janssen
  5. Medtronic
  6. Abbott
  7. Ferring Pharmaceuticals
  8. Hospira-Pfizer
  9. MSD
  10. Tillotts
  11. Mundipharma
  12. Mylan
  13. Warner Chilcott
  14. Ferring
  15. Biohit
  16. Celgene
  17. Hospira
  18. Kern Pharma
  19. Biogen
  20. Roche
  21. Sandoz
  22. Faes Farma
  23. Shire Pharmaceuticals
  24. Dr. Falk Pharma
  25. Tillotts Pharma
  26. Chiesi
  27. Casen Fleet
  28. Gebro Pharma
  29. Otsuka Pharmaceutical
  30. Vifor Pharma
  31. Amgen

Ask authors/readers for more resources

Background: Prevention and management of postoperative recurrence (POR) is a controversial field in Crohn's disease. The aim of this survey was to report common practice in real-life settings. Methods: An 11-question survey was distributed among gastroenterologists attending the 14th European Crohn's and Colitis Organisation (ECCO) congress. Results: Postoperative endoscopy to assess recurrence was routinely performed within 12 months by 87% of respondents. Forty-six percent of clinicians reported to maintain endoscopic assessment in routine follow-up even after first negative colonoscopy. Most respondents (60%) considered starting postoperative immunoprophylaxis in naive patients if one or more known risk factors were present. The number of risk factors was an important driver for prescribing biologics over immunosuppressants for 60% of respondents. In case of fistulizing phenotype, perianal disease, or concomitant colonic involvement, the majority of physicians reported to start an immediate prophylaxis in 85, 98 and 88% of patients, respectively. A significant percentage of clinicians were more prone to an endoscopy-driven treatment in long-standing disease after failure of thiopurines (51%) and elderly (43%). Conclusion: Endoscopy within the first year after surgery to assess POR has become routine in most centres. The high rate of early prophylaxis with expensive biologics despite missing solid evidence highlights the need for more randomized trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available